SCHEDULE: Federated Hermes Boosts aTYR PHARMA Stake to 10.76%

Federated Hermes, Inc. and its affiliated entities reported a beneficial ownership of 10.76% in aTYR PHARMA INC common stock as of September 30, 2025.

Summary

• Federated Hermes, Inc. and its affiliates beneficially own 10,544,437 shares of aTYR PHARMA INC common stock.
• This ownership represents 10.76% of aTYR PHARMA INC's outstanding common stock.
• The filing is an Amendment No. 10 to a Schedule 13G, indicating a change in previously reported ownership.
• The shares are held by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc.
• The reporting persons, including Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and its trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue), disclaim beneficial ownership of the reported securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of aTYR PHARMA INC.

Sentiment

Score: 7

Explanation: The filing indicates a substantial, passive institutional investment in aTYR PHARMA INC by Federated Hermes, Inc. and its affiliates, which can be viewed positively as a vote of confidence from a major financial institution.

Positives

• Significant institutional investment by Federated Hermes, Inc. in aTYR PHARMA INC, which can be viewed as a vote of confidence from a major financial institution.
• The investment is stated to be in the ordinary course of business and not for control purposes, suggesting a passive, long-term investment perspective.

Negatives

• No specific negative information for aTYR PHARMA INC is contained within this ownership disclosure.

Risks

• The reporting persons explicitly state that the filing should not be construed as an admission of beneficial ownership, and they expressly disclaim beneficial ownership of the reported securities.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding aTYR PHARMA INC's future performance or strategic direction.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• This statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

Industry Context

This filing is a routine disclosure of institutional ownership, indicating that aTYR PHARMA INC continues to attract and maintain investment from major financial institutions like Federated Hermes, Inc. It does not provide specific insights into broader industry trends or competitive positioning beyond this investment interest.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and liquidity for aTYR PHARMA INC's stock.
• Company Management: Awareness of a significant institutional shareholder, though the investment is stated to be passive and not for control.

Key Dates

Recommendation

The filing indicates a substantial, passive institutional investment by Federated Hermes, Inc. in aTYR PHARMA INC. While this signals institutional confidence, the filing is purely an ownership disclosure and does not provide new operational or financial performance data to warrant a change from a 'hold' position without further analysis of the company's fundamentals.

Keywords

aTYR PHARMA INC, Federated Hermes, Schedule 13G, beneficial ownership, institutional investment, common stock, biotechnology, pharmaceuticals